Retinal Vein Occlusion

Retinal vein occlusion (RVO) is a common retinal vascular disorder, second only to diabetic retinopathy in prevalence. RVO occurs when blood vessels in the retina become blocked, preventing blood flow and initiating a cascade of events that impair vision. It is a common complication of high blood pressure, high cholesterol, and diabetes. While there is no cure, current treatments to manage vision loss include intravitreal anti-VEGF injections, laser therapy, and steroid injections. Frequent dosing requirements and poor patient compliance with existing therapies drive significant demand for alternative treatment approaches.

Model Overview

EyeCRO has validated a mouse model of RVO designed to test therapeutic intervention on retinal degeneration. Venous injection of the photo-activator dye Rose Bengal is combined with laser treatment to allow for precise and robust thrombus formation and retinal vein occlusion. Following injection of the dye, a thermal laser is used to photocoagulate up to 3 different retinal veins in a single eye.

Typical Endpoints

  • OCT (longitudinal retinal thickness in the area of occlusion, up to 2 weeks)
  • In vivo fluorescein angiography (retinal vascular leakage)
  • Immunohistochemistry (retinal cell death)
  • Biochemical analysis of inflammation

Representative Data

RVO OCT

Interested in this model?
We are happy to share more about study design options, endpoints, or timelines.
Contact us to discuss your study goals.